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Abstract: The histopathology of cardiac xenograft rejection has evolved
over the last 20 yr with the development of new modalities for limiting
antibody-mediated injury, advancing regimens for immune suppression,
and an ever-widening variety of new donor genetics. These new technol-
ogies have helped us progress from what was once an overwhelming
anti-Gal-mediated hyperacute rejection to a more protracted anti-Gal-
mediated vascular rejection to what is now a more complex manifesta-
tion of non-Gal humoral rejection and coagulation dysregulation. This
review summarizes the changing histopathology of Gal- and non-Gal-
mediated cardiac xenograft rejection and discusses the contributions of
immune-mediated injury, species-speciﬁc immune-independent factors,
transplant and therapeutic procedures, and donor genetics to the overall
mechanism(s) of cardiac xenograft rejection.
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Introduction
Deceased human organ donation rates do not meet
the demand for clinical transplantation. Changes
in donor deﬁnition and legislation have not
substantially closed this gap in supply. Potential
alternatives to cardiac allotransplantation include
mechanical devices, regenerative medicine applica-
tions, and xenotransplantation. Genetic modiﬁca-
tions of organ-source pigs in concert with evolving
immunosuppressive strategies have resulted in sig-
niﬁcant progress in cardiac xenotransplantation.
Cardiac xenograft survival in the heterotopic pig-
to-primate model has increased from a few hours
to a median survival of 3 months with individual
survival beyond 8 months [1–3].
Major contributions to this progress have been
recognition of (i) the importance of antibodies
directed to pig galactose-a1,3-galactose (Gal) epi-
tope in xenograft rejection [4–7]; (ii) the potential
protective eﬀects of human complement regulatory
protein (hCRP) transgenes [8,9]; and (iii) the devel-
opment of therapies to deplete [10–14] or block
anti-Gal antibody in vivo [15–19], culminating in
the genetic elimination of the Gal antigen from the
donor pig (the a1,3-galactosyltransferase gene
knockout [GTKO] pig) [20–22]. Xenotransplanta-
tion is now in an era of anti-non-Gal antibody-
mediated rejection.
The authors, members of the NIAID-supported
Consortium on Immunobiology of Xenotransplan-
tation, have extensively reported on cardiac xeno-
transplantation. In this review, the group assesses
the histopathology of anti-non-Gal antibody-medi-
ated cardiac xenograft rejection and discusses the
implications this may have for future research
strategies.
Early anti-non-Gal antibody-mediated rejection: ﬁrst evidence of
a new histopathology
The initial barrier to xenotransplantation was hy-
peracute rejection (HAR) caused by complement-
mediated endothelial cell (EC) destruction directed
by preformed anti-Gal antibody. The histopathol-
ogy of HAR is predominantly characterized by
rapid graft failure and widespread intravascular
hemorrhage (Fig. 1A,C, Table 1). This is accom-
panied by vascular antibody, complement, and
ﬁbrin deposition with the formation of platelet-rich
thrombi (not shown) [23–27]. Improved xenograft
survival was not reliably achieved until methods
were developed to block the eﬀects of complement
and anti-Gal antibody. Early attempts depleted
anti-Gal antibody through pig-speciﬁc organ
perfusion [10,23,24], plasmapheresis, or aﬃnity
immunoadsorption [11–14,28,29]. These studies
demonstrated the dominant role of anti-Gal anti-
body in graft rejection [14,28–30], but provided
only temporary antibody reduction. An induced
anti-Gal antibody response led to delayed
xenograft rejection (DXR) also characterized by
interstitial hemorrhage, vascular antibody and
complement deposition with diﬀuse platelet-rich
ﬁbrin thrombosis (Fig. 1B, Table 1). Unlike HAR,
DXR occurs over the course of days to weeks, and
vascular antibody and complement deposition,
nearly universal in HAR, is more variable in DXR.
This is due in part to the eﬃcacy of diﬀerent
modalities (hCRP transgenic organs, cobra venom
factor, plasmapheresis, or soluble complement
inhibitors) used to limit antibody-dependent com-
plement-mediated injury.
Enduring reduction in anti-Gal antibody in vivo
was successfully achieved using continuous or
intermittent infusion of non-antigenic Gal poly-
mers [1,19,27,31–34]. Of relevance to anti-non-Gal
antibody-mediated GTKO pig xenograft rejection,
these earlier studies are notable in that, for the ﬁrst
time, transplants using Gal polymers largely
blocked the eﬀects of both preformed and post-
transplant-induced anti-Gal antibody, leading to a
striking change in the histopathology of xenograft
rejection [1,33,35]. Whereas anti-Gal-mediated
DXR showed prominent interstitial hemorrhage
(Fig. 1B), the histopathology of graft failure under
conditions that eﬃciently blocked anti-Gal anti-
body was largely characterized by microvascular
thrombosis with only focal evidence of interstitial
hemorrhage (Fig. 1D, Table 1). This thrombotic
microangiopathy (TM) was ﬁrst explicitly noted by
Houser using a poly-l-lysine Gal polymer and
CD55 (hDAF) transgenic pig hearts [35]. The same
histology was also reported using CD46 transgenic
donor hearts and a polyethylene glycol Gal poly-
mer [1,33,36,37] and in GTKO cardiac xenografts
[3]. In the polymer studies, rejected cardiac xeno-
grafts uniformly showed vascular antibody deposi-
tion, ﬁbrin, and platelet thrombi, with myocardial
coagulative necrosis and ischemia (Fig. 2). Vascu-
lar complement deposition, variably measured by
detection of C3, C4d, C5b, and C5b-9, was incon-
sistently observed and may be dependent on donor
genetics. Lymphocytic inﬁltration of the graft was
generally minimal or absent.
This change in histopathology was attributed to
sustained depletion of anti-Gal antibody. A recent
histopathology comparison of cardiac xenografts
under conditions where pre-transplant anti-Gal
antibody was uniformly depleted and post-trans-
plant induction of anti-Gal antibody was either
partially muted by immunoapheresis, blocked by
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in vivo Gal polymers, or made irrelevant using
GTKO donor hearts supports this conclusion [38].
Under these conditions, the major histopathologic
features of developing and terminal xenograft
rejection were the same for each group (Fig. 3A).
Early evidence of rejection included vascular anti-
body deposition at 30 min after organ reperfusion
and, at later time points, consistent myocyte vacu-
olization in the absence of appreciable microvascu-
lar thrombosis (Fig. 3B). As rejection progressed,
based on the systemic release of cardiac troponin,
diﬀuse microvascular thrombosis developed, even-
tually leading to myocardial coagulative necrosis
and ischemic changes (Fig. 3C). At the time of
graft failure, all three groups showed prominent
microvascular thrombosis and coagulative necrosis
with minimal interstitial hemorrhage or lympho-
cytic inﬁltration (Fig. 3D). Taken together, these
results suggest that muting or elimination of the
acute eﬀects of preformed anti-Gal antibody
reduced the intensity of humoral rejection, which
likely limited the extent of interstitial hemorrhage.
Gene expression analysis of these transplants sug-
gested that a chronic state of antibody-mediated
EC activation likely contributed to the develop-
ment of TM [38].
Histopathology of GTKO cardiac xenotransplantation
The initial study of heterotopic GTKO cardiac
xenotransplantation reported no HAR and a med-
ian survival of 78 days [3]. This study was
performed in recipients with minimal preformed
anti-non-Gal antibody and used a well-established
immunosuppressive regimen based on lymphocyte
depletion, cobra venom factor (CVF), and chronic
costimulation blockade. Recipients showed general
hyporesponsive lymphocyte reactivity and had lit-
tle evidence of an induced antibody response.
A detailed histology and immunohistology anal-
ysis was consistent with a progressive humoral
rejection, resulting in widespread platelet-rich/
ﬁbrin-rich microvascular thrombi, myocardial
ischemia, and necrosis, with focal interstitial hem-
orrhage [39]. Importantly, the degree of rejection
was shown to be proportional to the level of vascu-
lar immunoglobulin and complement deposition,
increased expression of recipient porcine tissue fac-
tor (pTF), formation of ﬁbrin–platelet thrombi,
and the frequency of EC apoptosis. Graft failure
was also associated with a proportionate loss of
CD39 expression. Cellular inﬁltration of the graft
was minimal to mild and consisted mainly of
monocytes with few lymphocytes.
A B
C D
Fig. 1. Histopathology of xenograft rejection. The ﬁgure shows a comparison between anti-Gal and non-Gal antibody-mediated car-
diac xenograft rejection. All panels show hematoxylin and eosin staining. A. Anti-Gal antibody-induced hyperacute rejection of a
Gal-positive heart showing widespread intravascular hemorrhage characteristic of HAR. B. Anti-Gal antibody-mediated delayed
xenograft rejection (DXR) of a Gal-positive heart on post-operative day 10. The rejected graft shows vascular injury, hemorrhage,
and coagulative necrosis characteristic of anti-Gal-mediated DXR. C. Non-Gal antibody-mediated hyperacute rejection of a GTKO
heart 90 min after reperfusion showing intravascular hemorrhage similar to that seen in Gal-mediated HAR (panel A). D. Non-Gal-
mediated DXR on post-operative day 92 of a Gal-positive CD46 transgenic heart showing thrombotic microangiopathy. The recipi-
ent in panel D received chronic alpha-Gal polymer infusions to block anti-Gal antibody. Original magniﬁcation A and C 4009, B
and D 2009 (Panel C adapted from: McGregor CGA, et al. Cardiac xenotransplantation: progress toward the clinic. Transplanta-
tion. 2004: 78: 1569–1575.)
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These transplants showed that using GTKO
organs eﬀectively eliminated a role of anti-Gal
antibody in graft rejection, but also clearly demon-
strated the signiﬁcance of anti-non-Gal antibody
in the development of graft failure. Under these
conditions, non-Gal-mediated GTKO heart rejec-
tion involved three major processes: (i) direct
antibody-mediated EC injury, supported by the
vascular deposition of antibody and terminal
complement complexes in 7 of 8 grafts; (ii) EC
activation, as evidenced by increased expression of
pTF and vascular loss of CD39; and (iii) EC apop-
tosis that occurred relatively late in the rejection
process. The development of these pathophysio-
A B C
Fig. 2. Anti-non-Gal antibody-mediated cardiac xenograft rejection. This ﬁgure shows the immunohistopathology of anti-non-Gal
antibody-mediated DXR for Gal-positive CD46 pig heart protected from anti-Gal antibody by continuous infusion of an a-Gal
polymer. A. Hematoxylin and eosin stain showing ischemic injury and myocardial coagulative necrosis in a graft with ongoing rejec-
tion at 113 days. B. Immunohistochemical staining of the same graft showing positive vascular IgM deposition. The insert shows
immunoﬂuorescence staining for ﬁbrin. C. Negative immunohistochemical staining for C5b. The insert shows a low level of positive
immunoﬂuorescence staining for CD41 platelet thrombi. All photomicrographs at 2009. (Immunohistochemical staining in panels
A–C adapted from: McGregor CGA, et al. Cardiac xenotransplantation: progress toward the clinic. Transplantation. 2004: 78:
1569–1575.)
Table 1. Histology of cardiac xenograft rejection
Donor type HAR DXRa TM/CCa,b
Wild type
• Acute rapid graft failure within
minutes or hours after reperfusion
• Extensive vascular antibody and
complement deposition
• Prominent vascular injury and
hemorrhage
• Some platelet and ﬁbrin thrombi
may be presentThe expected
outcome for transplantation of
wild-type organs into untreated
recipients
• Occurs days to weeks after
transplantation
• Vascular antibody and variable
complement deposition
• Intravascular injury and hemorrhage
• Prominent diﬀuse platelet-rich
ﬁbrin thrombosis
• Coagulative necrosis Requires
pre-transplant therapies to limit
immediate antibody- and
complement-mediated graft injury
• Occurs days to weeks after
transplantation
• Vascular antibody and
complement deposition is
variable
• Minimal vascular hemorrhage
• Myocyte vacuolization.
• Fibrin- and platelet-rich
microvascular thrombosis.
• Coagulative necrosis Requires
rigorous pre- and post-
transplant prevention of
an anti-Gal antibody response
GTKO Histology is comparable to wild-type donor
organs, but the frequency of GTKO HAR is
dramatically lower.
• Occurs days to months after
transplantation.
• Vascular antibody and complement
deposition is variable
• Minimal intravascular hemorrhage
• Myocyte vacuolization
• Fibrin- and platelet-rich microvascular
thrombi
• Coagulative necrosisTypical
histopathologic picture in GTKO
organs in immune-suppressed
recipients with low-to-moderate levels
of anti-non-Gal antibody.
aDXR and TM/CC typically show low levels of polymorphonuclear neutrophil and macrophage graft vascular adhesion and infiltration, with little apparent lymphocytic infiltrate.
In TM/CC, increased levels of macrophage infiltration may accompany systemic innate cell activation.
bTM and CC may occur individually or in combination. TM is localized to the graft, and CC is an intravascular process with significant recipient thrombocytopenia and systemic
fibrin consumption.
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logic processes progressed in parallel with histo-
logic changes (microvascular thrombosis and coag-
ulative necrosis), suggesting that TM within the
graft resulted from the eﬀects of immunoglobulin
and complement, that is to say immune-mediated
rejection.
However, other processes may also contribute
signiﬁcantly to graft thrombosis. These include
systemic activation of recipient innate immune
cells, leading to consumptive coagulopathy (CC)
[40–42], as well as pig-speciﬁc deﬁciencies in the
regulation of thrombosis [43–46]. Recent histologic
analysis of GTKO graft failure is helping to iden-
tify when and how these processes may contribute
to xenograft rejection.
Early anti-non-Gal-induced immune injury
Cytotoxic anti-non-Gal antibody, with a titer typi-
cally 2- to 3-fold lower than anti-Gal antibody, is
broadly present in human and non-human primate
serum [47]. Despite this reduced titer, non-Gal
antibody can in some instances have signiﬁcant
deleterious eﬀects. A classic case of HAR has been
reported in a GTKO heart [48,49]. Immediately
post-transplant, the graft showed good contractil-
ity. A 30-min biopsy showed normal myocardium,
but with extensive vascular antibody deposition
and moderate focal C5b deposition. By 90 min
post-transplant, contractility had ceased and the
histology showed widespread intramyocardial
hemorrhage (Fig. 1C, Table 1) with extensive vas-
cular antibody and complement deposition [see
Fig. 2 in Reference 49]. The timing, gross appear-
ance, and histopathology of this graft were entirely
consistent with an antibody-mediated HAR and
did not diﬀer from the histology of anti-Gal anti-
body-mediated HAR (Fig. 1A).
a1,3-galactosyltransferase gene knockout pigs
heart xenografts have also been reported to
undergo early immune injury from preformed anti-
non-Gal antibody, which did not result in HAR
[34,41]. In these studies, GTKO graft survival was
<1 day in the absence of immune suppression, but
was extended to 2 to 12 days with “partial”
immune suppression and up to 8 weeks with a
A
D
B
C
0
1
2
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4
CN MV MT CON HM
Sc
or
e
Pheresis
Gal polymer
GTKO
Fig. 3. Histopathologic features of DXR in the absence of the eﬀects of anti-Gal antibody. Data from three treatment groups are
shown. (i) Recipient treated by plasmapheresis (Pheresis) to deplete anti-Gal antibody pre- and post-transplant; (ii) Chronic Gal-
polymer-treated recipient to block anti-Gal antibody in vivo; and (iii) Transplantation of a GTKO donor heart. A. Histologic fea-
tures of DXR in the absence of acute anti-Gal antibody. The intensity of major histopathologic features at explant (mean histology
score  standard error of the mean) are shown. (Abbreviations: CN, coagulative necrosis; MV, myocyte vacuolization; MT, micro-
vascular thrombosis; CON, congestion; HM, hemorrhage.) B–D. Progressive development of DXR (H&E 4009). B. Cardiac biopsy
from an apheresis-treated recipient (day 13 of 53) showing early (stage 1) DXR characterized by myocyte vacuolization with minimal
microvascular thrombosis or systemic release of cardiac troponin. Insert shows a stage 1 biopsy (day 47 of 71) from a GTKO/CD55
heart (H&E 2009). C. Interim biopsy (day 15 of 21) of a heart from an apheresis-treated recipient showing progressive (stage 2)
DXR, characterized by increased levels of microvascular thrombosis (arrows) and developing coagulative necrosis. Insert shows a
stage 2 biopsy (day 14 of 26) of a GTKO/CD55 heart (H&E 2009). D. Representative histopathology of grafts at explant in all three
groups (Portions of this ﬁgure adapted from data in Tazelaar HD, Byrne GW, McGregor CG. Comparison of Gal and
non-Gal-mediated cardiac xenograft rejection. Transplantation. 2011: 91: 968–975).
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“full” regimen. Xenograft rejection was complex,
as the grafts, regardless of the eﬃciency of immune
suppression, showed evidence of both humoral
rejection, in the form of vascular antibody and
complement deposition, and recipient innate
immune cell activation. The innate cell activation
was manifested as CC (deﬁned by thrombocytope-
nia, low ﬁbrinogen levels, prolongation of pro-
thrombin and activated partial thromboplastin
times, bleeding) and as a signiﬁcantly increased
level of intragraft neutrophil inﬁltration with a
marked increase in recipient baboon tissue factor
(bTF) expression from intragraft and graft adher-
ent intravascular monocytes and macrophages
(Fig. 4A–D, Table 1). Activation of recipient
innate immune cells and induction of bTF expres-
sion have also been reported in kidney xenograft
recipients subject to CC [42].
These results demonstrate that preformed anti-
non-Gal antibody contributes to early graft injury,
but also show clearly that under some conditions,
systemic activation of the recipient innate immune
cells can occur. This activation, resulting in
increased recipient bTF expression on peripheral
blood mononuclear cells, may be stimulated
through antibody-mediated rejection or through
cell–cell interactions that are independent of anti-
body-induced EC activation [42,50,51]. In both
cases, activated recipient innate cells can exacer-
bate ongoing humoral injury or directly contribute
to intragraft thrombosis.
Coagulation and graft failure
The diﬀerential expression of TF either from circu-
lating recipient monocytes or from donor graft
endothelium (described above) is a key observa-
tion, which suggests that a combination of distinct
mechanisms—local non-Gal antibody-mediated
immune injury and systemic recipient innate cell
activation—may contribute to overall intragraft
thrombosis. What is clear is that similar hetero-
topic and orthotopic xenograft survival can be
obtained with [3,35,41] and without [1,33,36,52,53]
exogenous anti-coagulation and that to date, the
thrombogenic process leading to terminal graft
failure remains resistant to all forms of tested clini-
cal anti-coagulation [3,36,37,52–54]. In the era of
GTKO donor pigs, with the elimination of anti-
Gal antibody-mediated rejection, the questions
arise as to which of these mechanisms—systemic
recipient monocyte activation or antibody-medi-
ated intragraft EC activation—is the dominant
stimulus for terminal intragraft thrombosis (rejec-
tion) and how best to prevent this process.
Systemic activation of recipient innate cells may
lead to CC, as has been variably reported after pig-
to-primate kidney, heart, and hematopoietic
cellular xenotransplantation [30,40,55,56]. CC is
not, however, universally observed [24,28,29,32,
37,54,57,58] and therefore may not be a de facto
inherent property of porcine organs. We suggest
that a combination of four major factors—(i) anti-
A
D
B
C
Fig. 4. Expression of recipient TF in
cardiac xenotransplantation.
Immunohistochemical staining for
recipient baboon tissue factor (bTF)
expression in rejected cardiac xenografts.
A. Staining for bTF in pig heart grafts that
rejected at day 12. B. bTF expression at
8 weeks. Both photomicrographs in A and
B show strong TF staining in thrombosed
vessels and less staining in the interstitium
(arrows) (9600). C and D. Colocalization
of bTF (red stain) and macrophages
(stained for CD68, brown) in heart grafts
excised on day 12 (C) and at 8 weeks (D)
is indicated by arrows (9600)
(Reproduced with permission from
Ezzelarab M, et al. Transplantation 2009;
87: 805–812).
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body-mediated injury; (ii) pig-speciﬁc immune-
independent factors; (iii) transplantation and cer-
tain transplant-related therapies; and (iv) donor
porcine genetics—need to be considered as poten-
tial factors that contribute to recipient innate cell
activation and its role in CC (Table 2).
Antibody-mediated injury
The systemic release of anaphylatoxin C5a appears
to be a key component of antibody-mediated
injury, which may also secondarily promote
systemic recipient innate cell activation. In
xenotransplantation, C5a is most often produced
through complement activation by antibody-medi-
ated injury or as a consequence of CVF adminis-
tration to deplete complement [59]. Elevated levels
of C5a, reported in hemodialysis patients [60], sug-
gest that plasmapheresis to remove anti-pig anti-
body may also increase circulating levels of C5a
[10–14]. C5a is a potent inﬂammatory peptide that
bridges the complement and coagulation cascades
[61], promotes thrombosis [62,63], and contributes
to innate and adaptive immune responses [64].
Antibody-mediated release of C5a within the graft
can induce TF expression in pig ECs, recruit neu-
trophils and monocytes to the xenograft, induce
TF expression on recipient neutrophils, and sensi-
tize monocytes to express inﬂammatory cytokines
[65]. The systemic release of C5a by CVF, while
not suﬃcient to induce frank CC, may activate
recipient neutrophils and monocytes and potenti-
ate their response to inﬂammatory mediators pro-
duced from humoral injury to the graft. C5a
release may contribute to the frequency of graft-
inﬁltrating neutrophils and expression of bTF
observed in hearts showing a mixture of humoral
rejection and recipient innate cell activation.
Pig-specific immune-independent factors
There are also pig-speciﬁc immune-independent
factors that may contribute to development of CC.
These include well-known incompatibilities involv-
ing porcine von Willebrand factor (vWF) and
thrombomodulin (TBM), which have been recently
reviewed [66]. Porcine vWF binds to human GpIb
on platelets to cause a shear-independent aggrega-
tion. Because of this unusual cross-species interac-
tion, accumulation of porcine vWF in the
circulation of xenograft recipients over time would
be anticipated to increase the tendency for systemic
coagulation [67]. Likewise, the ineﬃcient graft-spe-
ciﬁc production of activated protein C by porcine
TBM may predispose the xenograft to intragraft
thrombosis [68].
Cross-species cellular interactions between por-
cine ECs and resting human platelets and mono-
cytes may also lead to systemic platelet activation
and EC apoptosis [50,69]. Co incubation of por-
cine EC with resting human platelets or monocytes
leads to platelet activation and platelet and mono-
cyte expression of human TF. Activated platelets
in turn express CD154 and can induce a CD154-
dependent activation of resting porcine ECs. In
vitro studies show that porcine EC can also be acti-
vated by binding of human polymorphonuclear
neutrophils (PMNs) and natural killer (NK) cells
[70,71]. PMN binding to pig ECs under ﬂow condi-
tions leads to intracellular calcium spikes and EC
activation not seen in allogeneic EC [72]. This
interaction results in a PMN respiratory burst,
increased inﬂammatory gene expression, and ele-
vated cytokine expression [73]. These changes may
further recruit PMNs, monocytes, and leukocytes
to the graft; increase transendothelial leukocyte
migration; enhance monocyte and PMN TF
expression; exacerbate intragraft inﬂammation and
thrombosis; and increase EC sensitivity to NK
cytotoxicity [70,74]. These cellular interactions
occur independent of xenoreactive antibody and
could, in principle, create an ampliﬁcation cycle
promoting CC by increasing systemic activation of
recipient platelets and monocytes and intragraft
activation of vascular ECs. It remains to be deter-
mined to what extent these in vitro cellular eﬀects
contribute to cardiac xenograft rejection.
Anti-CD154 mAb has been used as a chronic
immunosuppressive agent in several pig-to-primate
organ and cellular xenotransplantation models.
Combined with other therapies, anti-CD154 mAb
eﬃciently blocks induction of anti-pig antibody
[3,31,35,41,42,75]. Use of an anti-CD154 mAb
therapy has often been associated with the devel-
opment of CC [3,31,34,41,55], although not with
Table 2. Factors that may influence the development of thrombotic
microangiopathy in GTKO pig cardiac xenografts
1. Immune-mediated injury
Complement-mediated EC injury
Anti-non-Gal antibody-mediated EC activation
2. Pig-specific immune-independent factors
Porcine vWF, TFPI, and thrombomodulin incompatibility
Recipient platelet/monocyte and porcine EC interactions
3. Transplantation or treatment factors
Xenotransplant model: heterotopic vs. orthotopic
Complement targeting: cobra venom factor, C1 Inhibitor (C1INH)
Antibody depletion: plasmapheresis, extracorporeal immunoadsorption
Anti-CD154 mAb
Anti-coagulation: heparin, aspirin.
4. Donor genetics
Antigen reduction (GTKO, Neu5Gc-KO)
Human complement regulatory protein transgene expression (CD46, CD55, CD59)
Anti-coagulation and anti-thrombotic transgene expression
(TBM, EPCR, CD39, TFPI)
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every anti-CD154 mAb-based regimen [76,77]. One
hypothesis suggests that activated platelets, with
CD154 surface expression, may be cross-linked by
anti-CD154 mAb to promote thrombosis [78].
Whether this mechanism is active in allotransplan-
tation remains under investigation [79]; however in
xenotransplantation, platelet activation through
cross-species non-immune cellular interactions
such as those discussed above and chronic admin-
istration of anti-CD154 may increase the risk of
CC. Taken together, severe perioperative platelet
loss, a common sign of CC, could be due to
insuﬃcient immunosuppression (strong immune-
mediated eﬀects), intense non-immune cross-spe-
cies cellular interactions, or milder cellular
interactions exacerbated by reagents such as CVF
and anti-CD154 mAb. Paradoxically, under some
conditions, anti-CD154 mAb may also block
CD154-dependent platelet adhesion to graft ECs
and thereby inhibit EC activation [69].
Transplantation and treatment factors
The transplantation model—heterotopic or ortho-
topic—may aﬀect the development of CC, which
has been primarily associated with heterotopic car-
diac xenotransplantation [31,35,41,55]. In some
instances, this may be due to sluggish blood ﬂow
and intrachamber thrombus formation detected by
echocardiography in heterotopic transplants. Con-
ceivably, soluble products derived from coagula-
tion within the chambers of the heart may enhance
both systemic coagulopathy and microvascular
thrombosis within the xenograft. This process
would likely not account for early perioperative
thrombocytopenia.
In contrast, CC has generally not been reported
after orthotopic cardiac xenotransplantation in the
context of conventional immunosuppression [58,80–
87] despite the requirement for cardiopulmonary
bypass, which is known to activate platelets. The
general absence of post-operative CC in orthotopic
xenotransplantation may be aﬀected by the need for
full anti-coagulation at the time of the transplant
and/or the higher ﬂow rate of blood through the
graft throughout the post-operative course.
Donor genetics
An increasing variety of genetically modiﬁed pigs
are becoming available (Table 3), which may help
to minimize systemic coagulation and prolong
graft survival. The most immediately accessible are
GTKO donor pigs expressing hCRP transgenes.
Transgenic expression of an hCRP creates an
enhanced intrinsic barrier to complement activa-
tion and would be expected to minimize produc-
tion of C5a. This may help to inhibit both
antibody-mediated injury to the graft and systemic
recipient innate cell activation. A recent compari-
son of heterotopic cardiac xenografts using GTKO
and GTKO/CD55 hearts under carefully matched
immune suppression showed a reduced frequency
of C5b deposition in GTKO/CD55 hearts consis-
tent with improved complement restriction in the
graft [49]. Expression of CD55 appeared to prevent
early graft injury as hyperacute rejection of a
GTKO heart was observed in this study. Similar
protection from early graft failure has been
reported using other hCRPs [88 and A.M. Azimzadeh,
unpublished observation]. In this matched study,
expression of CD55 did not, however, lead to
improved overall graft survival (GTKO median
survival 21 days, range 0 to 128 days, and GTKO/
hCD55 median survival 28 days, range 15 to
54 days). This may be due to chronic EC activa-
tion, as elicited non-Gal antibody can lead to com-
plement-independent EC activation, which is not
aﬀected by hCRP expression [51]. Intragraft gene
expression studies were consistent with the inter-
pretation that graft rejection occurred resultant to
chronic EC activation [49].
Table 3. Genetically modified pigs currently available for xenotrans-
plantation researcha
Gal antigen deletion or “masking”
a 1,3-galactosyltransferase gene knockout (GTKO)
Human H-transferase gene expression (expression of blood type O antigen)
Endo-b-galactosidase C (reduction in Gal antigen expression)
Human N-acetylglucosaminyltransferase III gene expression (GnT-III)
cytidine monophosphate-N-acetylneuraminic acid hydroxylase (Neu5Gc-KO)
Complement regulation by human complement regulatory gene expression
CD46 (membrane cofactor protein)
CD55 (decay-accelerating factor)
CD59 (protectin or membrane inhibitor of reactive lysis)
Anti-coagulation, anti-thrombotic, anti-inflammatory, and apoptosis gene
expression or deletion
human tissue factor pathway inhibitor (TFPI)
human thrombomodulin (TBM)
human endothelial protein C receptor (EPCR)
human CD39 (ectonucleoside triphosphate diphosphohydrolase-1)
porcine von Willebrand factor deficiency (vWF natural mutant)
human A20 (tumor necrosis factor-alpha-induced protein 3)
human HO-1 (heme oxygenase-1)
human TNFRI-Fc (tumor necrosis factor-alpha receptor 1-Fc)
Suppression of cellular immune response by gene expression or down-regulation
porcine cytotoxic T-lymphocyte antigen 4 expression (CTLA4-Ig)
human modified CTLA4-Ig expression (LEA29Y)
CIITA-DN expression (swine leukocyte class II knockdown)
human TRAIL (tumor necrosis factor-alpha-related apoptosis-induced ligand)
human HLA-E b2-microglobulin expression (inhibits human natural killer cells
cytotoxicity)
human CD47 (regulates species-specific CD47-dependent macrophage
interactions)
Human FAS ligand expression (CD95L)
aModified from Ekser B et al. [Ref 86].
Pigs with combinations of genetic modification, for example GTKO with added
transgenes, are available.
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Cardiac xenotransplantation has also been
reported using GTKO pigs expressing human
CD46 [2]. In this study, immune suppression con-
sisted of a unique combination of anti-thymocyte
globulin, anti-CD20 mAb, anti-CD154 mAb, and
CVF induction therapy, with mycophenolate mo-
fetil and anti-CD154 mAb maintenance therapy,
with daily aspirin and continuous heparin infusion
post-transplant. With “full immune suppression”,
median graft survival was 71 days, but with
“partial immune suppression” (anti-CD20 mAb
withheld), median graft survival decreased to
8 days, and histopathology showed evidence of
rejection. The eﬀectiveness of human CD46 expres-
sion to prevent early complement-mediated injury
was unclear in this study and may have been con-
founded by early CC.
Pigs expressing human TBM have been reported
([89,90] and (Ayares D. Personal Communica-
tions)). Expression of human TBM appears to cor-
rect the molecular incompatibility between pigs
and primates and may signiﬁcantly improve
thromboregulation within the graft. Additional
new genetics (Table 3) may further improve
thromboregulation (e.g., tissue factor pathway
inhibitor [TFPI], endothelial protein C receptor
[EPCR], CD39) or reduce inﬂammation (HO-1,
TNFRI-Fc, A20, CD39) and ischemia–reperfusion
injury (CD39, HO-1) [91,92]. Expression of these
genes may act to limit recipient innate cell activa-
tion and reduce the tendency toward CC.
The potential eﬀects of common therapies,
including plasmapheresis, CVF, and anti-CD154
mAb, discussed above, are individually not suﬃ-
cient to induce CC. Rather, it appears to be the
combination of therapies, donor genetics, and
transplant model that may predispose toward the
development of CC. In future, a focus on the
orthotopic transplant model, elimination of CVF
therapy, or achieving complement inhibition with
newer complement agents such as eculizumab
[93,94]; substitution of anti-CD154 mAb by
other biologic agents; and the use of GTKO
donors with intrinsic complement regulation and
genetically modiﬁed to reduce the pig-speciﬁc
immune-independent factors (e.g., that contribute
to coagulation dysregulation) should minimize
the tendency for recipient innate cell activation
and CC and may further diminish graft failure
from TM.
Orthotopic cardiac xenotransplantation
Most cardiac xenotransplantation studies have
used the abdominal heterotopic model where the
main focus has been to extend xenograft survival
by developing an optimal combination of donor
genetics and immune suppression. This has been a
successful approach as median heterotopic graft
survival has increased to 3 months, cellular rejec-
tion is minimal, and the induction of anti-non-Gal
antibody is generally blocked [1–3]. Replication of
these results in life-supporting transplants would
show the eﬃcacy of cardiac xenotransplantation
and support limited clinical testing [95]. Orthotopic
cardiac xenotransplantation is a more technically
challenging model, and both the number of groups
who have performed these transplants and the
number of transplants are limited [58,80–86].
Overall reported orthotopic graft survival ranges
from <1 to 57 days, but with only 9 of 54 reported
grafts surviving for >2 weeks [87]. Recipient death
most often occurs either within the ﬁrst 48 h due
to perioperative cardiac xenograft dysfunction
(PCXD) or, in recipients that survive beyond 48 h,
from post-operative complications. Early ortho-
topic transplants using CD55 transgenic organs
without speciﬁc therapy to block anti-Gal anti-
body had graft survival of 5–39 days [80,81]. The
histopathology of organ rejection included intense
vascular IgM and complement deposition, throm-
bosis, and interstitial hemorrhage, which was con-
sistent with anti-Gal antibody-induced DXR
[96,97]. Subsequently, Gal polymer therapy was
used to block anti-Gal antibody in recipients of
CD55 transgenic grafts [84,85]. In this case, rejec-
tion correlated with the induction of anti-non-Gal
antibody, and the histology was consistent with
TM, including antibody and complement deposi-
tion, ﬁbrin thrombosis, and myocyte necrosis.
In studies using Gal-positive CD46 hearts with Gal
polymer therapy, or GTKO/CD55 hearts, graft
survival ranged from 14 to 57 days without appar-
ent rejection [86,98], but with complications associ-
ated with immunosuppressive drug therapy.
Explanted hearts exhibited vascular antibody bind-
ing with minimal complement deposition. There
were variable levels of ﬁbrin deposition and little
evidence of CD41-stained platelet thrombi
(Fig. 5A–C). Histologic injury, characterized by
myocyte necrosis, varied from minimal to mild in 4
of 5 recipients.
All studies involving orthotopic cardiac xeno-
transplantation have reported a high frequency of
PCXD in which 40–60% of transplants failed
within the ﬁrst 48 h [87]. A similar failure rate is
not observed after abdominal heterotopic cardiac
xenotransplantation, where post-operative graft
function, based on contractility, is generally satis-
factory. The etiology of PCXD is unknown, but its
prevalence after orthotopic xenotransplantation
suggests that it results from the physiologic
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demands placed on the graft. In our experience,
using Gal polymer and CD46 hearts or GTKO:
CD55 donor hearts, the diagnosis and histopathol-
ogy of PCXD-aﬀected heart (absent clear iatro-
genic events) are distinct from HAR or DXR.
PCXD hearts weaned from cardiopulmonary
bypass are reliant on continuous and often high
levels of inotropic support. Repeated attempts to
wean these hearts from inotropes are unsuccessful
and lead to a progressive negative cycle of
deteriorating cardiac function. The histology of
PCXD-aﬀected hearts (see Fig. 1C in Reference
[98]) shows vascular antibody deposition with
occasional diﬀuse ﬁbrin deposits. There is however
minimal platelet thrombi, vascular congestion,
complement deposition, or thrombosis [58,80–86].
It seems likely that severity of PCXD is aﬀected by
heightened porcine sensitivity to ischemia–reperfu-
sion injury and the eﬀects of acute anti-non-Gal
antibody-mediated injury.
In the absence of rejection, life-supporting car-
diac xenografts explanted between 9 and 57 days
universally exhibit vascular antibody deposition
(Fig. 5B). Generally, these grafts showed minimal
or focal histologic evidence of rejection and were
largely free of platelet thrombi (insert Fig. 5C). In
an unbiased genomewide analysis of porcine gene
expression, both (i) grafts explanted due to PCXD;
and (ii) surviving xenografts recovered at recipient
death, but without frank rejection, exhibited an
array of changes in cardiac gene expression indica-
tive of inﬂammation and myocardial injury [98].
Some of these same changes in gene expression
have also been noted in rejected heterotopic car-
diac xenografts [99]. These observations indicate
that despite life-supporting cardiac function and
well-preserved myocardial histology, surviving
orthotopic xenografts remain under continuous
adverse stimulation, likely due to immune-medi-
ated injury. The altered pattern of gene expression
detected in these explanted hearts is compelling
evidence of protracted EC activation. This suggests
that in the presence of vascular antibody deposi-
tion, the general absence of microvascular throm-
bosis is maintained by a dynamic hemostatic
regulatory response, which counters the throm-
botic eﬀects of antibody-induced EC activation.
Further understanding of this dynamic process will
likely open new opportunities for therapeutic and
genetic interventions, which aﬀect the balance of
thrombosis and ﬁbrinolysis.
Future strategies
Future strategies in xenotransplantation research
should be directed toward improving graft
survival, thereby enhancing the eﬃcacy of this
potential clinical therapy. For cardiac xenotrans-
plantation, we believe that this goal can be reached
by focusing on three main issues.
First, for clinical orthotopic cardiac xenotrans-
plantation, it is essential to limit the frequency of
fatal PCXD. PCXD appears to be a multifactorial
phenomenon related to anti-non-Gal antibody-
induced immune injury and pig-speciﬁc sensitivi-
ties, such as the eﬀects of transplantation trauma,
cardiopulmonary bypass, ischemia–reperfusion
injury, and vasospasm. Reducing the frequency of
PCXD will likely require the development of
improved methods of organ preservation and early
therapeutic interventions to limit acute post-oper-
ative immune injury. For example, cariporide, a
type I sodium–hydrogen exchange inhibitor, has
been shown to limit ischemia–reperfusion injury in
a porcine cardiac transplant model and improve
organ preservation [100,101]. This or a similar
pharmaceutical approach to improve organ pres-
ervation coupled with the transplantation of
GTKO hearts expressing one or more hCRPs with
possible antibody depletion prior to transplant
A B C
Fig. 5. Histology of orthotopic cardiac xenografts. A. Hematoxylin and eosin stain of heart explanted after 57 days. B and C Immu-
nohistology on day 57 for vascular IgM (B) and C5b (C). Insert in B shows moderate ﬁbrin staining. Insert in C shows minimal to
negative staining for CD41 platelet thrombi.
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may be eﬀective to alleviate early antibody-medi-
ated graft injury and reduce the frequency of fatal
PCXD. Prophylactic use of anti-cytokine reagents,
such as etanercept (Enbrel) to block TNF-a
[102,103] or anakinra (Kineret) [104] to block IL-1
may be used to limit perioperative inﬂammation
of vascular endothelial cells [105] and may further
reduce the potential for PCXD. Donor hearts
expressing elevated levels of CD39 are resistant to
ischemia–reperfusion injury and may represent a
non-pharmaceutical solution to modulate PCXD
[106].
Second, the prevalence of vascular antibody and
complement deposition in rejected GTKO cardiac
xenografts, even in the apparent absence of an
induced antibody response, indicates that a better
understanding of the nature of anti-non-Gal anti-
body and further optimization of immune suppres-
sion would be valuable. In non-human primates,
anti-pig non-Gal antibody responses to porcine
EC proteins involved in autoimmunity, thrombo-
sis, inﬂammation, and complement regulation
(CD9, CD59, CD46, EPCR, Annexin 2A) [48] and
an induced anti-glycan response directed to a car-
bohydrate encoded by the porcine glycosyltransfer-
ase, a1,4-N-acetylgalactosaminyltransferase have
been observed [107,108]. In human sera, the
induced anti-non-Gal antibody response to porcine
proteins is not as well deﬁned [109]. Humans,
however, have preformed antibody to N-glycolyl-
neuraminic acid (Neu5Gc), which is a unique anti-
glycan response not present in non-human
primates [110–113]. Anti-Neu5Gc antibody is esti-
mated to constitute 7–13% of the preformed anti-
pig non-Gal human antibody repertoire [114], and
an induced anti-Neu5Gc antibody response has
been detected after clinical porcine islet transplan-
tation [115]. The potential for anti-Neu5Gc anti-
body to contribute to cardiac xenograft rejection
remains unclear because anti-Neu5Gc antibodies
are not present in non-human primates and there-
fore do not contribute to histopathology in experi-
mental pig grafts [116–118]. Recently, pigs with a
targeted mutation in cytidine monophosphate-
N-acetylneuraminic acid hydroxylase (CMAH)
have been produced on the GTKO background
[119]. These double knockout pigs, which lack
expression of Gal and Neu5Gc, are a promising
development for clinical xenotransplantation,
which remains to be tested.
The relative contribution of anti-glycan com-
pared with anti-protein antibody to xenograft
rejection as well as the pathogenicity of any indi-
vidual non-Gal speciﬁcity is not clear. This is an
important point, as additional genetic modiﬁcation
to eliminate or substitute common porcine protein
target antigens is probably not feasible, but elimi-
nation of porcine expression of other glycans (in
addition to Gal) is. The pathogenicity however of
antibodies to other glycans, other than Gal, has
not yet been shown [120–122].
Little is known about the origin of non-Gal anti-
bodies bound to the vasculature of cardiac xeno-
grafts. Are these germ-line-encoded antibodies,
cross-reactive aﬃnity-matured antibody derived
from an unrelated immune challenge, or the
product of an induced xenograft-speciﬁc immune
response? Depletion of mature B cells periopera-
tively has been associated with better graft out-
come and reduced humoral sensitization [1,2], but
this approach is not expected to aﬀect existing
plasma cells. Additional new therapeutic modali-
ties, such as the proteasome inhibitor, bortezomib
[123], may be useful to deplete plasma cells, and
existing immune suppression regimens may be
modiﬁed to incorporate B-cell-speciﬁc therapeu-
tics, such as lymphoblast-B (belimumab) [124,125],
to further limit any weak induction of anti-non-
Gal antibody.
Third, it is essential to evaluate the contribution
that new pigs expressing anti-coagulant transgene
function will have on xenograft rejection, throm-
bosis, and systemic coagulopathy. Transgenic pigs
expressing human TBM, EPCR, or CD39 have
been produced [90,106,126–129]. Expression of
human TBM appears to correct the primary por-
cine EC deﬁciency in activated protein C produc-
tion [126]. Improved thrombin regulation may also
reduce the T-cell-dependent adaptive immune
response as thrombin-activated porcine aortic
ECs induce increased human T-cell proliferation
[130].
Expression of CD39 in conjunction with CD73
leads to local production of adenosine, which is a
potent inhibitor of thrombosis. Transgenic mice
expressing human CD39, although fully viable,
show an increased capacity to produce adenosine,
have impaired platelet aggregation, and prolonged
bleeding times. In a mouse cardiac transplant
model, these mouse hearts are protected from
thrombosis [131]. In a warm renal ischemia model,
resistance to ischemia–reperfusion injury has been
demonstrated [131,132]. Hearts from transgenic
pigs expressing human CD39 similarly showed a
reduction in infarct size after coronary occlusion
and reperfusion [106].
Initial experience with heterotopic heart trans-
plantation in the hCD39, hCRP, and hTBM multi-
transgene GTKO pig-to-baboon model indicates
that in the presence of CVF and anti-CD154 mAb
therapy, high level expression of hCD39 by the
porcine vasculature is associated with less throm-
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bocytopenia and better maintenance of plasma
ﬁbrinogen levels in recipient baboons (B. Ekser,
unpublished observation).
These data suggest that high level expression of
hCD39 on this genetic background with concur-
rent validated expression of hCRP may have two
beneﬁts: ﬁrst to prevent ischemia–reperfusion
injury that might help prevent PCXD and second
as an anti-thrombotic to prevent intragraft throm-
bosis. Further testing these and other new
genetically modiﬁed donor swine will be required
in both heterotopic and orthotopic cardiac trans-
plant models to gauge the impact of these genes on
PCXD, intragraft thrombosis, and systemic
coagulation parameters in recipient baboons. In
any case, CVF should be avoided as GTKO
pigs expressing hCRPs are now available, and
CVF may exacerbate recipient innate cell
activation.
Conclusions
Cardiac xenograft survival has improved signiﬁ-
cantly since the introduction in the early 1990s of
the ﬁrst transgenic pigs in which a hCRP was
expressed [8,9]. GTKO pig organs have elimi-
nated the need for speciﬁc anti-Gal antibody
therapy, and multiple new transgenic modalities
are being developed to regulate both the immune
response and coagulation activation. Drugs with
greater speciﬁcity toward B cells and antibody-
producing plasma cells have been approved,
which may improve immune regulation. PCXD
has been identiﬁed as a hurdle, and aggressive
investigation of this phenomenon is necessary. As
new genetic and pharmacologic technologies to
improve porcine cardiac preservation, control
humoral and cellular immune responses, and
limit thrombosis and inﬂammation are tested, we
anticipate further signiﬁcant improvements in
cardiac xenograft survival, which will support
clinical application.
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